Skip to main content
Premium Trial:

Request an Annual Quote

Biocept KRAS Liquid Biopsy Test

Biocept has launched a new blood-based KRAS mutation test to help physicians identify patients who might benefit from currently available targeted therapies. According to the company the high sensitivity of its technology could also allow the test to be used for monitoring patients' responses to treatment and the progression of their disease during the course of therapy.

The quantitative Target Selector KRAS assay joins Biocept's existing portfolio of liquid biopsy tests for melanoma, breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.